首页> 外文学位 >Targeted gene alteration in SMA patient cells: Genetic conversion of an SMN2 gene to SMN1 increases full-length SMN production.
【24h】

Targeted gene alteration in SMA patient cells: Genetic conversion of an SMN2 gene to SMN1 increases full-length SMN production.

机译:SMA患者细胞中的靶向基因改变:SMN2基因向SMN1的遗传转化增加了全长SMN的产生。

获取原文
获取原文并翻译 | 示例

摘要

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease that is characterized by the loss of alpha motor neurons leading to muscle atrophy and eventually death. SMA is caused by a mutation or deletion in the survival motor neuron (SMN) gene. This gene is present in two copies, SMN1 and SMN2, with each differing by 5 nucleotide substitutions, all of which are silent mutations. However, at position +6 in exon 7 of SMN2 there is a T in the place of a C, which causes an exonic splice enhancer, and the majority of transcripts produced from SMN2 are lacking exon 7. Patients with SMA rely on the number of copies of SMN2 and, for this reason; disease severity is inversely related to SMN2 copy number. Currently there is no cure or adequate treatment available but many studies are underway to develop therapies that facilitate an increase in full-length SMN. Some of these are histone deacetylase inhibitors (HDI) that work in increasing global transcription. They have been found to increase SMN transcript as well as protein but their effects are transient and short-lived. Another promising treatment for SMA comes in the form of gene repair with the use of single stranded oligonucleotides (ssODN). In fact, it was observed that in patient cells, the ssODN-mediated gene conversion was able to alter the base in SMN2 to become SMN1-like that was evaluated on the genomic level by several assays; quantitative PCR, restriction enzyme digestion, and cycle sequencing. The gene conversion led to an increase in full-length SMN mRNA and this effect was observed out to 7 days after oligonucleotide treatment. Most importantly, the cells treated with oligonucleotide were able to produce statistically significant increases in the amount of cellular gems, which is a universal measure for the SMN protein. Thus, the use of ssODN-mediated gene therapy in SMA patients' cells was successful and the ssODN led to a robust increase in full-length SMN mRNA and a significant increase in cellular gems.
机译:脊髓性肌萎缩症(SMA)是一种常染色体隐性隐性神经肌肉疾病,其特征是丢失了导致肌萎缩并最终死亡的α运动神经元。 SMA是由存活运动神经元(SMN)基因的突变或缺失引起的。该基因有两个拷贝SMN1和SMN2,每个拷贝有5个核苷酸取代,它们都是沉默突变。但是,在SMN2的第7外显子的+6位置,有一个T代替C,这导致外显子剪接增强子,而从SMN2产生的大多数转录物都缺少第7外显子。 SMN2的副本,因此;疾病严重程度与SMN2拷贝数成反比。目前尚无治愈方法或适当的治疗方法,但正在进行许多研究以开发有助于增加全长SMN的疗法。其中一些是组蛋白脱乙酰基酶抑制剂(HDI),可用于增加整体转录。已经发现它们可以增加SMN转录本以及蛋白质,但是它们的作用是短暂且短暂的。 SMA的另一种有希望的治疗方法是使用单链寡核苷酸(ssODN)进行基因修复。实际上,已经观察到在患者细胞中,ssODN介导的基因转化能够改变SMN2中的碱基,使其变成SMN1样,可以通过几种测定在基因组水平上进行评估。定量PCR,限制酶消化和循环测序。基因转化导致全长SMN mRNA增加,并且在寡核苷酸处理后7天观察到这种效果。最重要的是,用寡核苷酸处理的细胞能够产生统计学上显着的细胞宝石数量增加,这是SMN蛋白的通用指标。因此,在SMA患者的细胞中成功使用了ssODN介导的基因疗法,并且ssODN导致了全长SMN mRNA的显着增加以及细胞宝石的显着增加。

著录项

  • 作者

    Callahan, Stephanie.;

  • 作者单位

    University of Delaware.;

  • 授予单位 University of Delaware.;
  • 学科 Biology Molecular.;Biology Genetics.
  • 学位 M.S.
  • 年度 2009
  • 页码 89 p.
  • 总页数 89
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号